George Magrath, M.D., Chief Executive Officer of Opus Genetics added “We believe these ... a non-selective alpha-1 and alpha-2 adrenergic antagonist being investigated to reduce pupil size ...

This year’s Annual Meeting of Stockholders (the “Annual Meeting”) of Opus Genetics, Inc. (“Opus” or the “Company”) is scheduled to be held on April 30, 2025. This meeting is a ...